Diagnosis Guide for Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma (NHL) is a cancer that originates in the lymphatic system, part of the immune system, and can affect various lymphoid tissues. With over 60 subtypes, each having different progression rates, treatment protocols, and prognoses, NHL presents unique challenges. Understanding the diagnosis process, treatment options, and managing side effects can empower patients and caregivers with knowledge and support.

1. Understanding the Types of Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma is categorized by cell origin (B-cell or T-cell), growth rate (indolent or aggressive), and specific markers. Knowing the exact NHL type is critical to choosing the right treatment.

B-Cell Lymphomas: Account for about 85% of NHL cases, originating in B-lymphocytes.

• Diffuse Large B-Cell Lymphoma (DLBCL):
  • This is the most common and aggressive type of NHL, characterized by rapid growth. Immediate treatment is typically necessary, and DLBCL often responds well to standard therapies, though relapses are possible.
• Follicular Lymphoma:
  • A slower-growing or “indolent” lymphoma, follicular lymphoma may not require immediate treatment and is often managed with regular monitoring. It can, however, transform into a more aggressive form over time.
• Mantle Cell Lymphoma:
  • A rare, generally aggressive B-cell lymphoma that may be resistant to standard therapies. Mantle cell lymphoma often requires combination therapy approaches, including chemotherapy, targeted therapy, and sometimes stem cell transplants.
• Burkitt Lymphoma:
  • A highly aggressive and fast-growing lymphoma that is more common in children and young adults. Burkitt lymphoma often requires intensive treatment, including high-dose chemotherapy.

T-Cell Lymphomas: Less common than B-cell lymphomas, and generally more challenging to treat.

• Peripheral T-Cell Lymphoma (PTCL):
  • This group includes several aggressive lymphomas originating from mature T-cells and often requires complex, multi-agent treatment protocols due to lower response rates.
• Anaplastic Large Cell Lymphoma (ALCL):
  • A rare subtype of T-cell lymphoma that can vary in aggressiveness. ALCL is associated with the ALK gene in certain cases, which can impact treatment.

Growth Rate Classification

• Indolent Lymphomas: Slow-growing types, like follicular lymphoma, which may not need immediate treatment. These types are often managed with “watch-and-wait” approaches, with treatment beginning only if symptoms appear or the disease progresses.
• Aggressive Lymphomas: Rapidly growing types, such as DLBCL and Burkitt lymphoma, typically require prompt, intensive treatment.

2. The Diagnosis Process for Non-Hodgkin Lymphoma

The diagnosis of NHL involves several steps to determine the exact subtype, spread, and characteristics of the lymphoma, all of which are crucial for selecting the most effective treatment.

Medical History and Physical Examination

• Symptom Assessment: Common symptoms include swollen lymph nodes, fever, night sweats, weight loss, fatigue, and sometimes skin itching. B-symptoms (fever, night sweats, weight loss) can indicate a more advanced disease stage.
• Physical Examination: The doctor will check for swollen lymph nodes, especially in the neck, underarms, and groin, and assess the spleen and liver for any signs of enlargement.

Lymph Node Biopsy

A biopsy is essential to confirm an NHL diagnosis and determine the specific subtype. Types of biopsies include:

• Excisional Biopsy: Involves removing an entire lymph node or a larger tissue sample, providing the most comprehensive view of the disease and is the preferred biopsy method.
• Core Needle Biopsy: In cases where a full excision isn’t feasible, a needle is used to collect a smaller tissue sample. It’s less invasive but may provide limited information.

The biopsy sample is examined to determine the lymphoma type and subtype, cell morphology, and specific genetic or protein markers that can influence treatment decisions.

Imaging Tests

Imaging helps visualize the extent of lymphoma spread (staging) and identify involved organs.

• CT Scan: Cross-sectional imaging to detect lymph node enlargement, tumors, and organ involvement, particularly in the chest, abdomen, and pelvis.
• PET Scan: PET scans highlight areas of high metabolic activity, which may indicate lymphoma presence and can help in staging and post-treatment evaluation.
• MRI: Used for lymphomas near the brain, spinal cord, or other soft tissues. MRI can provide detailed images of nervous system involvement.
• Chest X-Ray: May reveal enlarged lymph nodes or lymphoma involvement in the chest area, particularly useful for staging and initial assessments.

Blood Tests

Blood tests assess overall health, evaluate organ function, and sometimes reveal indirect signs of lymphoma involvement.

• Complete Blood Count (CBC): Measures white blood cells, red blood cells, and platelets, revealing abnormalities that may indicate lymphoma spread to the bone marrow.
• Lactate Dehydrogenase (LDH): Elevated LDH levels can indicate aggressive disease or advanced stage.
• Liver and Kidney Function Tests: Important for assessing how well the body can tolerate treatments like chemotherapy.

Bone Marrow Biopsy

This biopsy checks if NHL has spread to the bone marrow and provides crucial information for staging.

• Procedure: A sample of bone marrow is taken from the hip bone using a needle. This procedure can confirm the extent of NHL involvement.
• Findings: Reveals the presence of lymphoma cells and can show how the disease has impacted healthy blood cell production.

Molecular and Genetic Testing

Molecular testing provides information on specific genetic mutations and markers that may guide targeted treatments.

• Flow Cytometry and Immunophenotyping: These tests analyze cell surface markers to confirm the NHL subtype, particularly useful for distinguishing B-cell and T-cell lymphomas.
• Cytogenetic Analysis: Detects chromosomal abnormalities, such as translocations (e.g., t(14;18) in follicular lymphoma) that are associated with specific NHL subtypes.
• Gene Expression Profiling: Determines the activity of certain genes, potentially influencing the choice of targeted therapies.

3. Understanding Biopsy and Imaging Results

The results of biopsies, imaging tests, and molecular analyses provide a complete picture of the type, extent, and behavior of NHL, which are essential for treatment planning.

Lymph Node Biopsy Results

• Type of NHL: Confirms if it is B-cell or T-cell lymphoma and identifies the specific subtype (e.g., DLBCL, follicular).
• Cell Morphology: Determines if cells are small or large, indicating indolent or aggressive behavior, respectively.
• Genetic Markers: Identifies mutations or translocations (e.g., BCL2 gene rearrangement) that can guide treatment and influence prognosis.

Imaging Results

• Tumor Size and Location: Determines the exact location and size of tumors or affected lymph nodes, essential for staging.
• Organ Involvement: Identifies the spread to organs, such as the liver, spleen, or bone marrow, impacting staging and treatment choices.
• Metabolic Activity: PET scans provide insight into disease activity, with higher uptake indicating more aggressive lymphoma.

Blood and Genetic Test Results

• Blood Count Abnormalities: Low levels of red blood cells, white blood cells, or platelets may suggest bone marrow involvement.
• Genetic Mutations: Specific genetic mutations (e.g., MYC gene in Burkitt lymphoma) can impact treatment and help tailor therapies to individual patients.

4. Staging of Non-Hodgkin Lymphoma

Staging NHL determines the extent of spread and guides the treatment approach. Each stage reflects how localized or widespread the disease is.

• Stage I: Involvement in a single lymph node region or a single organ outside the lymph nodes.
• Stage II: Involvement in two or more lymph node regions on the same side of the diaphragm or one organ and nearby lymph nodes.
• Stage III: Lymphoma is present in lymph node regions on both sides of the diaphragm, possibly involving the spleen or other nearby organs.
• Stage IV: Widespread lymphoma involving distant lymph nodes and other organs such as the liver, bone marrow, or lungs.

Lymphoma is also classified by “A” or “B”:

• A (Asymptomatic): No B-symptoms are present.
• B (Symptomatic): B-symptoms like fever, night sweats, and weight loss are present, often indicating a more advanced or aggressive disease.

Recently diagnosed and need help understanding treatment options? See Wellnest's guide for Treatment Options for Non-Hodgkin Lymphoma, Must-Have Items for Going Through Treatment, and Questions to Ask the Doctor.